On July 15, 2026, Cryo-Cell International Inc CCEL announced its financial results for the second quarter, revealing revenue of $7.8 million, a modest decline compared to $7.9 million during the same period last year. This slight dip highlights the challenges faced by the company in maintaining growth amidst a competitive landscape.
- Market Cap: $28.8 million
- GF Scoreā¢: 58/100, indicating average performance across key metrics
- Financial Strength: 4/10, suggesting potential vulnerabilities in financial stability
What's Behind the News?
The recent earnings report from CCEL indicates a slight decline in revenue, which could be a concern for investors looking for growth in a competitive healthcare market. The company is actively exploring operational measures to adapt to changing market demands, which may help improve its financial outcomes in the future. The healthcare providers and services industry is known for its rapid evolution, and companies like CCEL must continuously innovate to maintain their market position.
Cryo-Cell International Inc specializes in cellular processing and cryogenic storage, particularly focusing on the collection and preservation of umbilical cord blood and tissue stem cells. With a market cap of $28.8 million, CCEL operates in the healthcare sector, which is characterized by its potential for growth but also by significant competition. The company's ability to navigate these challenges will be crucial for its future performance.
How Is CCEL Valued?
Currently, GF Valueā¢ data is not available for CCEL. However, the company has a price-to-sales (P/S) ratio of 0.93, which is below the industry average, suggesting that the stock may be undervalued relative to its sales. Investors should consider this metric alongside other financial indicators when assessing the company's valuation. For more detailed information, visit the CCEL stock page.
What Does CCEL's GF Scoreā¢ Tell Us?
The GF Scoreā¢ ranks stocks from 0 to 100 based on five key aspects: Financial Strength, Profitability, Growth, Valuation, and Momentum. Stocks with higher GF Scoreā¢ values have been found to generate higher long-term returns (backtested 2006-2021).
| Metric | Rating |
|---|---|
| GF Scoreā¢ | 58 |
| Financial Strength | 4/10 |
| Profitability | 6/10 |
| Growth | 1/10 |
CCEL's GF Scoreā¢ of 58 indicates that while the company has some strengths, particularly in profitability, its growth prospects are limited, as reflected in its low growth rank. The financial strength rating of 4 suggests potential vulnerabilities, which investors should consider when evaluating the company's long-term viability. For further insights, check the CCEL stock page.
What Are Insiders Doing with CCEL Stock?
In the past 12 months, there have been five insider buys, indicating some level of confidence from those within the company. However, there have been no insider sells, which could suggest a stable outlook among current shareholders.
What This Means for Investors
Given the recent revenue decline and the company's average GF Scoreā¢, investors may want to approach CCEL with caution. While there are some positive indicators, such as insider buying, the overall financial strength and growth metrics suggest that the company faces challenges ahead. For the complete analysis, visit the CCEL stock page. You can also use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions
What is CCEL's GF Scoreā¢?
CCEL's GF Scoreā¢ is 58/100, indicating average performance across key metrics that assess the company's financial health and growth potential.
How is CCEL valued?
CCEL has a price-to-sales (P/S) ratio of 0.93, which suggests that the stock may be undervalued relative to its sales compared to industry peers.
What is CCEL's P/E ratio compared to historical?
CCEL does not currently have a P/E ratio available, but its financial strength is rated at 4/10, indicating potential vulnerabilities that investors should consider.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
